Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aadi Biosciences Inc (AADI)

Aadi Biosciences Inc (AADI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,251
  • Shares Outstanding, K 24,554
  • Annual Sales, $ 24,350 K
  • Annual Income, $ -65,770 K
  • 60-Month Beta 0.62
  • Price/Sales 1.79
  • Price/Cash Flow N/A
  • Price/Book 0.44
Trade AADI with:

Options Overview Details

View History
  • Implied Volatility 312.60% ( +163.08%)
  • Historical Volatility 50.74%
  • IV Percentile 94%
  • IV Rank 60.71%
  • IV High 495.27% on 04/19/24
  • IV Low 30.35% on 07/18/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 28
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 724
  • Open Int (30-Day) 1,562

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.66
  • Number of Estimates 4
  • High Estimate -0.58
  • Low Estimate -0.71
  • Prior Year -0.57
  • Growth Rate Est. (year over year) -15.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6630 +1.02%
on 04/25/24
2.4500 -31.43%
on 03/28/24
-0.4900 (-22.58%)
since 03/25/24
3-Month
1.6350 +2.75%
on 01/29/24
2.4700 -31.98%
on 03/04/24
-0.0500 (-2.89%)
since 01/25/24
52-Week
1.5500 +8.39%
on 01/18/24
8.6000 -80.47%
on 05/23/23
-6.3200 (-79.00%)
since 04/25/23

Most Recent Stories

More News
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...

AADI : 1.6800 (-5.62%)
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...

AADI : 1.6800 (-5.62%)
Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...

AADI : 1.6800 (-5.62%)
Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...

AADI : 1.6800 (-5.62%)
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...

AADI : 1.6800 (-5.62%)
Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically...

AADI : 1.6800 (-5.62%)
Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...

AADI : 1.6800 (-5.62%)
Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...

AADI : 1.6800 (-5.62%)
Aadi Bioscience, Inc. (AADI) Reports Q1 Loss, Tops Revenue Estimates

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 1.72% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AADI : 1.6800 (-5.62%)
TRVN : 0.4090 (+7.35%)
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically...

AADI : 1.6800 (-5.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Aadi Bioscience Inc. is a clinical-stage biopharmaceutical company. It focuses on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Aadi Bioscience Inc., formerly known as Aerpio Pharmaceuticals Inc., is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 1.8193
2nd Resistance Point 1.7847
1st Resistance Point 1.7323
Last Price 1.6800
1st Support Level 1.6453
2nd Support Level 1.6107
3rd Support Level 1.5583

See More

52-Week High 8.6000
Fibonacci 61.8% 5.9069
Fibonacci 50% 5.0750
Fibonacci 38.2% 4.2431
Last Price 1.6800
52-Week Low 1.5500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar